I appreciate the excellent service and the office manager following up with additional prescription information. I’m also glad they were able to add the prism that my previous clinic couldn’t provide.
Ron Williams
Thyroid Eye Disease and Orbital Surgery
The Standard Surgical Sequence
Thyroid eye disease surgery almost always follows a defined three-step order. Each step must be given time to settle before the next one begins. Skipping ahead or combining steps without careful selection can lead to outcomes that are difficult to correct.
Orbital decompression is the first and most critical step. The surgeon removes bone, fat, or both to expand the space inside the eye socket and allow the eye to settle back into a more natural position. Bone decompression is generally preferred while the disease is still active, and fat decompression is more commonly used once the disease is quiet. The choice of which walls to treat depends on imaging studies and a thorough examination.
Decompression reduces proptosis, relieves pressure on the optic nerve, and allows the lids to cover the eye more fully. It can also shift the position of the eye, which is why strabismus surgery often becomes necessary as the next step.
Strabismus (crossed or misaligned eyes) surgery is performed if double vision persists or develops after decompression. Eye muscle surgery repositions the muscles that move the eye so that both eyes work together again. Surgeons typically wait three to six months after decompression before performing this step, allowing the eye to settle into its new position so that the muscle adjustments are accurate.
- Muscle recession to release restriction and reduce misalignment
- Adjustable sutures that allow fine-tuning in the office the following day
- Single or staged muscle procedures depending on complexity
- Prism glasses used as a temporary bridge between steps
Eyelid surgery is always performed last, after eye position and alignment have fully stabilized. The upper lid muscle may be recessed to lower the lid, a spacer graft may be placed to increase lid height, or a lid-tightening procedure may be used. Lower lid procedures help the lid rise enough to cover and protect the eye. These final steps protect the cornea and significantly improve the overall appearance of the eyes.
Medical Treatments Before and After Surgery
Surgery is not always the first or only treatment for thyroid eye disease. Several medications can reduce inflammation, slow progression, and in some cases reduce the need for surgery or limit how extensive it needs to be. Your eye doctor and endocrinologist work together to choose the right medical approach for your disease activity level and severity.
Teprotumumab, sold under the brand name Tepezza, is the only medication specifically approved by the FDA to treat thyroid eye disease. It works by blocking a receptor that drives the inflammation and tissue expansion inside the orbit. It is given as a series of eight infusions, once every three weeks, and is most effective during the active phase of moderate-to-severe disease.
Teprotumumab has been shown to reduce proptosis and improve disease activity scores in many patients. However, studies indicate that approximately 30 percent of patients experience a return of disease activity within roughly 72 weeks of completing treatment, so ongoing monitoring remains important even after a successful course of infusions.
For active, moderate-to-severe thyroid eye disease, the standard first-line approach is intravenous methylprednisolone combined with oral mycophenolate sodium. This combination reduces inflammation during the active phase and may reduce the eventual need for surgery or limit the scope of procedures required.
- Intravenous methylprednisolone for active moderate-to-severe disease
- Oral mycophenolate sodium used in combination with steroids
- Selenium supplementation for mild disease
- Teprotumumab for active disease with significant proptosis
Comparative studies suggest that teprotumumab and tocilizumab, a medication that blocks a specific inflammatory signal, tend to produce better outcomes than rituximab for thyroid eye disease. Each option carries its own risk profile, cost, and availability. Your care team helps weigh these factors against your disease severity, activity, and overall health before making a recommendation.
Orbital Decompression Techniques
Orbital decompression is not a single procedure but a family of approaches tailored to each patient's anatomy and degree of crowding. The surgeon selects which walls of the socket to address and which technique to use based on your imaging, exam findings, and surgical goals.
Bone decompression removes parts of the walls of the eye socket, most commonly the medial wall (the inner wall near the nose), the floor, or the lateral wall (the outer wall). Removing these bony walls creates additional space so the enlarged tissues can redistribute outward rather than pressing the eye forward. The approach chosen depends on which walls need treatment and the surgeon's experience.
An endoscopic approach through the nose gives access to the medial wall without any skin incision and often requires coordination with an ear, nose, and throat specialist. Other approaches include a transconjunctival incision inside the lid, a lateral incision through a natural lid crease, or a transcaruncular incision at the inner corner of the eye.
Fat decompression removes some of the excess orbital fat that has accumulated behind the eye. It is most often used during the quiet phase of the disease when proptosis needs to be reduced without the added complexity of bone removal. In more advanced cases, fat decompression may be combined with bone removal for a greater effect.
In carefully selected patients with stable disease and suitable anatomy, orbital decompression, strabismus surgery, and eyelid surgery can all be performed in a single operation. This approach has been shown to be effective in appropriate candidates and may reduce the total number of procedures and recovery periods required.
Not every patient is a candidate for this combined approach. Your surgeon will evaluate whether single-session or staged surgery is the safer and more effective choice for your specific situation.
Recovery After Each Procedure
Recovery from thyroid eye disease surgery varies depending on which procedure was performed. Each step has its own timeline, and understanding what to expect helps you plan your return to work and daily activities. Your care team provides detailed post-operative instructions and monitors your progress at each stage.
Most patients who undergo decompression of multiple socket walls spend at least one night in the hospital for monitoring. Swelling and bruising peak within the first 72 hours and then gradually improve. Sleeping with the head elevated, applying cool compresses gently, and avoiding nose blowing all help reduce complications and speed recovery.
Most patients are able to return to desk work within two to three weeks. Full settling of the eye's new position takes three to six months, which is why strabismus surgery is not considered until that period has passed.
Strabismus surgery is typically shorter and less intensive than decompression. The white of the eye often appears red for several weeks, and mild irritation is common. Lubricating eye drops provide comfort during this time. Double vision may improve quickly or take a few weeks to stabilize as the muscles adapt to their new positions.
- Redness of the white of the eye lasting several weeks
- Mild irritation managed with lubricating drops
- Possible adjustable-suture technique allowing fine-tuning the day after surgery
- Prism glasses for any residual misalignment that persists
Eyelid procedures generally have the shortest recovery period. Swelling typically settles within two weeks, though the final lid position may continue to refine over the following three months. Your surgeon tailors the technique to each lid, whether that means a muscle recession, a spacer graft, or a lid-tightening procedure, based on what the examination reveals.
Regular follow-up visits throughout all stages of recovery help your care team monitor eye pressure, visual function, and the health of the eye surface.
Working With Your Care Team
Thyroid eye disease involves multiple organ systems, so effective treatment requires more than one specialist. Understanding who is responsible for each part of your care helps you stay organized and informed throughout the process. Clear communication among all members of your team leads to better outcomes at every stage.
Your endocrinologist manages the underlying thyroid hormone levels that drive the disease. Your comprehensive ophthalmologist monitors the eye surface, cornea, and optic nerve throughout the process. An oculoplastic surgeon plans and performs orbital decompression and eyelid surgery. A strabismus specialist handles muscle surgery. Your primary care physician helps coordinate the overall plan and manages your general health.
- Endocrinologist for thyroid hormone management
- Ophthalmologist for surface and optic nerve monitoring
- Oculoplastic surgeon for decompression and eyelid procedures
- Strabismus surgeon for eye muscle realignment
- Primary care physician for overall coordination
Surgery is a major commitment, and no single path is right for every patient. Medical treatments such as teprotumumab may serve as an alternative or a bridge before surgery becomes necessary. A thorough conversation among you, your endocrinologist, and your oculoplastic surgeon weighs disease severity, activity level, prior treatment response, cost, and side effects before a plan is chosen.
Writing down your questions before appointments, bringing a trusted family member to major consultations, and keeping a simple notebook of decisions and next steps all make the process more manageable.
Thyroid eye disease can flare again even after successful surgery. Regular comprehensive eye exams, ongoing thyroid testing, and awareness of early warning signs allow your team to catch any recurrence before it causes serious harm. Patients who responded well to teprotumumab still carry a meaningful risk of relapse and should remain in follow-up care for the long term.
When to Seek Prompt Evaluation
Some symptoms of thyroid eye disease require urgent attention, while others can be addressed through a scheduled appointment. Knowing which symptoms are time-sensitive helps you act quickly when it matters most. If you are ever uncertain, it is always safer to contact your eye doctor sooner rather than later.
Contact your eye doctor promptly if you experience new dimming or blurring of vision, a fading of color saturation, severe pain with eye movement, or rapidly worsening bulging of the eye. These symptoms can signal compressive optic neuropathy, a condition in which the optic nerve is being compressed and vision may be at risk. Redness, dryness, and a wide-eyed appearance are less urgent but still deserve evaluation to plan appropriate care.
Coming to your consultation with prepared questions helps you make the most of the visit and leave with a clear understanding of your options. Bring any imaging studies, visual field test results, or records from prior treatment.
- How do you sequence decompression, strabismus, and eyelid surgery for my case?
- Am I a candidate for teprotumumab, or can you coordinate with someone who offers it?
- What is my specific risk of developing new double vision after decompression?
- Can I see results from similar cases at six and twelve months after surgery?
A second opinion is appropriate and encouraged for thyroid eye disease surgery. Different surgeons may recommend different sequences or techniques, and hearing more than one perspective helps you make an informed decision. Bring all available imaging and test results to each consultation so that every surgeon evaluates the same complete picture of your condition.
Frequently Asked Questions
The following questions address details that often come up after patients have learned the basics of thyroid eye disease surgery. These answers are intended to guide decision-making and help you know when to act.
For some patients with active, moderate-to-severe disease, teprotumumab reduces proptosis and inflammation enough to avoid decompression altogether or to reduce how extensive it needs to be. However, for patients whose disease has already quieted or who have severe structural crowding, surgery remains the most reliable way to create lasting change. Whether medication alone is sufficient depends on your individual disease activity, degree of proptosis, and response to treatment. Your care team helps you weigh both paths based on your specific findings.
Orbital decompression results are generally permanent because the bone and fat that are removed do not regrow. If the disease flares again, new inflammation can cause some swelling, but the expanded socket now has more room to accommodate it, which reduces the risk of severe consequences. A small number of patients require additional surgery if the disease recurs strongly. This is one of the reasons long-term monitoring remains important even after a successful procedure.
Strabismus surgery is most effective at eliminating double vision in primary gaze, meaning straight ahead, which is the position used for most daily tasks including reading, driving, and conversation. Some double vision in extreme up-gaze or side-gaze may persist because the restricted muscles do not always regain full range of movement. Prism glasses can correct residual misalignment that remains after surgery. Adjustable sutures allow your surgeon to fine-tune the result the day after the procedure, which improves accuracy for some patients.
Medical management becomes the primary focus when surgery is not an option. Preserving the eye surface with artificial tears, moisture-retaining eyewear, and careful positioning can reduce dryness and exposure-related damage. Systemic medications including teprotumumab or corticosteroids address active inflammation. In cases where the eye cannot close safely, a temporary tarsorrhaphy (a partial suture closure of the lids) or moisture chambers can protect the cornea until conditions allow a more definitive solution. Your care team tailors a protective plan to your specific limitations.
Smoking is the single strongest modifiable risk factor for thyroid eye disease, and it worsens outcomes at every stage of the condition. Patients who smoke have a higher likelihood of developing more severe disease, respond less well to medical treatment, and tend to heal more slowly and less predictably after surgery. Stopping smoking before treatment begins improves the effectiveness of both medication and surgery. Your care team can connect you with resources to support quitting if you currently smoke.
Your surgeon determines readiness for each subsequent step through a combination of examination, imaging, and time. After decompression, three to six months must pass before strabismus surgery so that eye position has stabilized. After strabismus surgery, the eye alignment must be consistent and settled before eyelid work begins, which typically takes a similar period. Rushing the sequence increases the chance of needing additional corrective procedures. Your surgeon sets clear milestone criteria at the start of treatment so you know what markers signal readiness for each next step.
Schedule a Consultation at NewView Eye Center
Thyroid eye disease surgery requires expertise, careful planning, and a team that communicates well at every stage. At NewView Eye Center, our eye doctors bring focused experience in medical and surgical eye care to patients throughout Northern Virginia, with the goal of protecting your vision and helping you feel like yourself again. We invite you to schedule a consultation so we can evaluate your condition, explain your options clearly, and work with you to build a plan that fits your needs.
What our Patients Says
Explore More
Find more information about our doctors, services, and technology that keep your eyes healthy and your vision at its best.